Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 12/20 | 0.34 |
| ▸ | PRCP | P42785 | 3/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30450613 | 0.74 | BRD4 (0.42) | HTTRAB9AALDH1A1 | |
| SCHEMBL20711430 | 0.74 | RAB9A (0.44) | HTTRAB9ATACR1ALDH1A1 | |
| SCHEMBL29736498 | 0.74 | DRD2 (0.50) | RAB9A | |
| SCHEMBL2019396 | 0.74 | SLC18A3 (0.43) | HTTRAB9AALDH1A1 | |
| SCHEMBL27394358 | 0.74 | DRD2 (0.50) | RAB9A | |
| SCHEMBL13676333 | 0.74 | DRD2 (0.46) | RAB9AALDH1A1 | |
| SCHEMBL17516295 | 0.72 | SLC18A3 (0.48) | HTTRAB9AALDH1A1 | |
| SCHEMBL17886516 | 0.71 | TP53 (0.46) | HTTRAB9A | |
| SCHEMBL18591774 | 0.70 | PRCP (0.42) | PRCP | |
| SCHEMBL13698256 | 0.68 | SLC6A2 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198705-B2 | Hybrid Amphotericin B derivatives with reduced toxicity | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198705-B2 | Hybrid Amphotericin B derivatives with reduced toxicity | ERG28, BAK1, MCL1 | HTT 2895/4885RAB9A 219/4885ACACB 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.